Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1951 3
1952 2
1953 8
1954 11
1955 9
1959 2
1960 2
1962 4
1964 1
1965 4
1966 1
1967 1
1968 4
1969 3
1970 5
1974 1
1980 2
1982 1
1983 5
1984 6
1985 2
1986 6
1987 7
1988 4
1989 6
1990 3
1991 5
1992 4
1993 9
1994 7
1995 4
1996 5
1997 6
1998 13
1999 9
2000 8
2001 11
2002 7
2003 9
2004 8
2005 5
2006 11
2007 16
2008 18
2009 13
2010 13
2011 19
2012 26
2013 15
2014 20
2015 27
2016 36
2017 29
2018 33
2019 36
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

477 results
Results by year
Filters applied: . Clear all
Page 1
Kidney stones
Khan SR, et al. Nat Rev Dis Primers 2016 - Review. Among authors: Gambaro G. PMID 27188687 Free PMC article.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic V, et al. N Engl J Med 2019 - Clinical Trial. PMID 30990260 Free article.
All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m(2) of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin-angiotensin system blockade. ...
All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m(2) of body-surface area and albu …
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group
Prezioso D, et al. Arch Ital Urol Androl 2015 - Review. Among authors: Gambaro G. PMID 26150027 Free article.
Diets with a calcium content ≥ 1 g/day (and low protein-low sodium) could be protective against the risk of stone formation in hypercalciuric stone forming adults. ...Despite the low level of scientific evidence, a low-protein (< 20 g/day) low-salt (< 2 g/day) diet with high hydration (> 3 liters/day) is strongly advised in children with cystinuria. ...
Diets with a calcium content ≥ 1 g/day (and low protein-low sodium) could be protective against the risk of stone formation in hyperc …
CKD Prevalence Varies across the European General Population
Brück K, et al. J Am Soc Nephrol 2016 - Clinical Trial. Among authors: Gambaro G. PMID 26701975 Free PMC article.
CKD stages 1-5 was defined as eGFR<60 ml/min per 1.73 m(2), as calculated by the CKD-Epidemiology Collaboration equation, or albuminuria >30 mg/g, and CKD stages 3-5 was defined as eGFR<60 ml/min per 1.73 m(2) CKD prevalence was age- and sex-standardized to the population of the 27 Member States of the European Union (EU27). ...
CKD stages 1-5 was defined as eGFR<60 ml/min per 1.73 m(2), as calculated by the CKD-Epidemiology Collaboration equation, or albuminuria …
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Trachtman H, et al. J Am Soc Nephrol 2018 - Clinical Trial. Among authors: Gambaro G. PMID 30361325 Free PMC article.
METHODS: In this phase 2, randomized, double-blind, active-control Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized, Double-blind, Active-Control, Dose-Escalation Study (DUET), patients aged 8-75 years with biopsy-proven FSGS, eGFR>30 ml/min per 1.73 m(2), and urinary protein-to-creatinine ratio (UP/C) ≥1.0 g/g received sparsentan (200, 400, or 800 mg/d) or irbesartan (300 mg/d) for 8 weeks, followed by open-label sparsentan only. End points at week 8 were reduction from baseline in UP/C (primary) and proportion of patients achieving FSGS partial remission end point (FPRE) (UP/C: ≤1.5 g/g and >40% reduction [secondary]). ...
METHODS: In this phase 2, randomized, double-blind, active-control Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor an …
477 results
Jump to page
Feedback